Janus Henderson Group PLC Purchases 3,948 Shares of Axsome Therapeutics, Inc. $AXSM

Janus Henderson Group PLC raised its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 26.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,052 shares of the company’s stock after acquiring an additional 3,948 shares during the quarter. Janus Henderson Group PLC’s holdings in Axsome Therapeutics were worth $3,219,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Axsome Therapeutics by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after purchasing an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Axsome Therapeutics by 2,407.9% during the first quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after purchasing an additional 7,320 shares during the period. Goldman Sachs Group Inc. increased its position in Axsome Therapeutics by 38.7% during the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after buying an additional 84,151 shares during the last quarter. Caxton Associates LLP acquired a new position in Axsome Therapeutics during the first quarter worth approximately $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Axsome Therapeutics by 29.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock valued at $8,735,000 after buying an additional 17,250 shares during the period. Institutional investors own 81.49% of the company’s stock.

Insiders Place Their Bets

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 4,660 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $213.95, for a total transaction of $997,007.00. Following the transaction, the chief executive officer owned 7,229 shares in the company, valued at $1,546,644.55. This trade represents a 39.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark Coleman sold 643 shares of Axsome Therapeutics stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $249.00, for a total value of $160,107.00. Following the sale, the director directly owned 30,389 shares of the company’s stock, valued at $7,566,861. This represents a 2.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 200,766 shares of company stock worth $46,685,646 over the last three months. 20.60% of the stock is currently owned by corporate insiders.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $212.74 on Friday. Axsome Therapeutics, Inc. has a 12 month low of $102.67 and a 12 month high of $260.19. The stock’s 50 day moving average is $236.95 and its 200-day moving average is $203.96. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. The company has a market capitalization of $10.95 billion, a price-to-earnings ratio of -57.03 and a beta of 0.65.

Analysts Set New Price Targets

A number of research firms have recently issued reports on AXSM. UBS Group raised their price objective on Axsome Therapeutics from $251.00 to $259.00 and gave the company a “buy” rating in a research report on Friday, April 10th. Royal Bank Of Canada increased their price target on Axsome Therapeutics from $302.00 to $304.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Needham & Company LLC raised their price target on Axsome Therapeutics from $225.00 to $255.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Wells Fargo & Company lifted their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $290.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $265.55.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.